China’s largest dairy company has collected Thailand’s top food-safety honour for the seventh consecutive year. Yili Group’s Thai subsidiary received the Thai FDA Quality Award again in 2026. It also earned the programme’s “Best of the Best” distinction for the second time.
The release credits quality systems, local sourcing and community spirit. It is a genuine regulatory achievement. It is also a carefully staged one, arriving at a delicate moment for the company back home.
What follows is the context the release leaves out. Behind it sit a shrinking Chinese dairy market, the $80 million acquisition behind this “local” subsidiary, and a fierce Thai ice cream war.
Why the Thai FDA Quality Award Lands Now
Three pressures shape the timing.
A home market in retreat
Yili’s domestic base is under strain. NielsenIQ data shows Chinese dairy consumption fell 8.6% in 2025, after more than two years of industry adjustment. Yili still grew: full-year 2025 revenue hit RMB 115.9 billion, and first-half 2026 revenue rose 4.1%. First-half net profit, though, fell roughly 20% on asset impairments.
Against that backdrop, every overseas win matters to the narrative. Yili has told investors its overseas business will sustain double-digit growth this year. Southeast Asia is the showcase region.
An award that doubles as diplomatic capital
The Thai FDA Quality Award comes from Thailand’s Ministry of Public Health. Past editions were handed over by a deputy prime minister. For a Chinese state-linked company in Southeast Asia, a regulator’s seal of approval beats any marketing campaign. Yili was the only Chinese-invested company to win the award in 2024, according to its own communications. Seven straight years builds a moat of institutional trust that money cannot buy quickly — only patiently.
The thirtieth-anniversary optics
This year marks three decades since Yili’s listing. The company has also announced a share-repurchase programme of up to RMB 2 billion and a payout commitment above 75%. A clean run of international awards, CSR donations and expansion news feeds the “global champion” chapter of that story. The August donation of 150,000 ice creams to the Thai government, folded into this release, belongs to the same script.
The Competitive Picture Behind the Award
Thailand’s ice cream market is worth roughly US$400–500 million, depending on the estimate. The top five players hold about 65% of it. The award winner competes there through Chomthana, the country’s largest domestic ice cream maker. Yili bought 96.46% of it in 2018 for about $80.5 million. Chomthana’s consumer brand is Cremo — the “popular choice among Thai consumers” the release celebrates.
The rivals are formidable. Unilever’s Wall’s and Magnum long dominated Thai freezers. Its December 2025 spin-off of the ice cream business into the standalone Magnum Ice Cream Company has only sharpened that focus. Nestlé, F&N Dairies, CP-Meiji and Dutch Mill’s I-Tim all hold significant share. Mixue, the cut-price Chinese chain expanding across Southeast Asia, pressures the value end.
Cremo sits in the top three by market share, on Yili’s own reporting, alongside the multinationals.
Thailand also matters as an export platform. The country commands about 72% of intra-ASEAN ice cream export value, roughly $140 million. Cremo now ships to 14 countries. Quality credentials in Thailand support the whole Southeast Asian push. Yili’s Indonesian ice cream revenue grew about 20% in the first half of 2026; in the Philippines, it doubled.
What the Data Shows About the Award Winner
The numbers behind the headlines are worth reading closely.
The Thailand operation, sized
Yili’s Thai subsidiary produces about 20,000 tons of ice cream annually. Its average annual sales growth ran above 16.5% over three years, on company disclosures from 2024. Cremo exports to 14 countries and regions, including Singapore, Malaysia, the United States, France and Australia. The release’s claims of 80% local sourcing and a 95% Thai workforce have appeared in earlier company communications. They match the post-acquisition playbook.
The parent’s scale, for contrast
The entire cold-drinks segment generated RMB 9.8 billion of Yili’s RMB 115.9 billion 2025 revenue. That is about 8.5%, even after growing 12.6%. Overseas ice cream revenue grew 10.2% in 2025. The bigger overseas numbers sit in milk powder.
Infant goat-milk formula revenue jumped 50.7% in 2025. Yili’s Ausnutria arm grew 30% in Canada in the first half of 2026. Thailand is a strategically important outpost, not a financial pillar.
The award, weighed
The Thai FDA Quality Award is a real regulator-run programme with document reviews, on-site inspections and sampling tests. It is not a pay-to-play trophy. But it is a certification of operational compliance, not a consumer quality ranking or a market-share measure. The release does not say how many companies won in 2026, or how many earned “Best of the Best.” Regulator awards across Southeast Asia routinely recognise dozens of enterprises annually. Seven consecutive wins is a strong record; it is not a moat on its own.
What’s New vs. What’s Repackaged
New: the 2026 award itself, and the second “Best of the Best” honour. Repackaged: nearly everything else. The 80% local sourcing figure, the 95% local workforce, the ERP-system quality story, the rabbit-ear ice cream and the pandan-and-nata-de-coco flavours all appeared in Yili’s earlier communications, including its 2024 Thailand factory tour. The August ice-cream donation was already publicised. Even the “World Integrally Sharing Health” vision is a long-standing corporate slogan.
What the release never mentions is Chomthana — the Thai company that supplies the factories, the brand and the distribution this entire story rests on.
The Question the Press Release Doesn’t Answer
What is the Thai business actually worth? No revenue, profit, market-share or volume figures for Thailand appear anywhere in the release. The “top three” and “16.5% growth” claims come from 2024 company materials, not audited results.
Second: what did winning cost? Awards predicated on traceability systems, cold-chain audits and ERP upgrades describe capital expenditure. Yili does not break out the Thai operation’s margins.
Third: how does the subsidiary plan to fight Mixue’s price war and the newly focused Magnum Ice Cream Company? On those questions, the release is silent.
What the Thai FDA Quality Award Streak Means for You
If you are an F&B company eyeing Southeast Asia, study the playbook rather than the award. Yili bought the local champion, kept the local brand and localised flavours. It sourced 80% domestically, staffed 95% locally and stacked a decade of regulator goodwill. That sequence — not any single honour — built the position.
If you follow Chinese consumer stocks, treat this as a signal of where growth has moved. Yili’s domestic liquid milk leads but barely grows; its overseas ice cream and goat-milk formula are the fast lines. Thailand is the proof point for a strategy the market will judge on consolidated numbers, not awards.
If you compete in Thai freezers, the landscape is shifting under you. Unilever’s ice cream spin-off, Mixue’s price pressure and Yili’s patient localisation squeeze the middle from both ends. A regulator-certified local champion with Chinese capital is a different competitor than either camp trained for.
Editor’s Note
This article draws on Yili‘s Thai FDA Quality Award press release of 22 September 2026, its 2024 Thailand communications and FY2025 and first-half 2026 results announcements, contemporaneous reporting on the 2018 Chomthana acquisition (Nikkei Asia, China Daily, Just Food, FoodNavigator-Asia), Mengniu’s FY2025 results for comparison, NielsenIQ consumption data cited by Yicai, and market-research estimates of Thailand’s ice cream market from MarkNtel, 6Wresearch, The Report Cubes and IndexBox, which vary by methodology. Market-share, growth and workforce figures for Yili Thailand are company disclosures and have not been independently audited. Nothing here is investment advice.